K Pharmaceuticals

K-Pharma is a clinical-stage biopharmaceutical company based in Japan that focuses on regenerative medicine and drug discovery using induced pluripotent stem (iPS) cell technology. Founded as a spin-off from Keio University, the company utilizes a proprietary platform to identify and develop treatments for central nervous system disorders and neurodegenerative diseases. Its lead candidate, KP-401 (ropinirole hydrochloride), is being repositioned for the treatment of Amyotrophic Lateral Sclerosis (ALS) following successful Phase 2 trials. K-Pharma is also developing KP-801, an iPS cell-derived neural stem/progenitor cell therapy for subacute spinal cord injury. The company aims to address significant unmet medical needs by combining cell therapy with innovative drug screening methods.